Invivyd shares are trading higher after the company announced PEMGARDA is available for purchase in the U.S. and said it sees initial FY24 PEMGARDA net product revenue guidance in the range of $150 million to $200 million.
Portfolio Pulse from Benzinga Newsdesk
Invivyd's stock price increased following the announcement that PEMGARDA is now available for purchase in the U.S., with the company projecting FY24 net product revenue for PEMGARDA to be between $150 million and $200 million.
April 05, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Invivyd's announcement of PEMGARDA's availability in the U.S. and its FY24 revenue guidance has positively impacted its stock.
The positive market reaction is likely due to the introduction of PEMGARDA in the U.S. market, a significant milestone for Invivyd. The provided revenue guidance for FY24 further boosts investor confidence in the product's market potential and the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100